French biotech company Abivax said new clinical trial data supports the safety and effectiveness of its experimental ...

U.S.-listed shares of Abivax climbed more than 25% in after-hours trading after the French biotech released new data aimed at ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative ...

New data from a Phase 3 maintenance study showed malignancy rates in line with what ulcerative colitis patients normally ...

Mirikizumab treatment is safe and efficacious for ulcerative colitis up to 152 weeks in those with and without previous biologic therapy failure. Mirikizumab treatment for 152 weeks is associated with ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. With ...

A medication used for psoriasis and psoriatic arthritis is proving to be an effective treatment for moderate to severe ulcerative colitis in the findings of a global study led by University of Chicago ...

AbivaxABVX stock crashed by more than a third Tuesday despite what one analyst called "best-case" results for a study of its ulcerative colitis treatment after several patients developed cancer. At ...

Glucagon-like peptide-1 (GLP-1) medications like semaglutide and tirzepatide are among the most talked-about drugs for weight loss and type 2 diabetes. But as their popularity has grown, so have ...

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...